Overview
Compare with UNITED GUARDIAN INC, cbdMD, Inc. or DSwiss Inc, or pick any stock.
- TickerCSCIF on OTC1
- IndustryPerfumes, Cosmetics & Other Toilet Preparations1
- HeadquartersToronto, Canada1
- Incorporated inOntario, Canada3
- Business addressC/O Norton Rose Fulbright Canada Llp, 222 Bay Street, Suite 3000, Po Box 53, Toronto, A6 M5K 1E73
- Filer categoryNon-accelerated filer3
See how the biggest companies compare on our leaderboards
7, 2026 the Company’s Common Shares became OTC quoted for trading on the OTC Market.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Active ingredients [member] brought in 94% of the revenue COSCIENS Biopharma Inc. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Active ingredients [member] | $7.1M | $8.5M | $7.0M |
| Biopharmaceutical | $1.1M | $461.0K |
Business segments
Active ingredient [member] brought in 94% of the revenue COSCIENS Biopharma Inc. broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2023 | 2024 | 2025 |
|---|---|---|---|
| Active ingredient [member] | $7.1M | $8.5M | $7.0M |
| Biopharmaceutical | $1.1M | $461.0K |
Regions
United states [member] brought in 61% of the revenue COSCIENS Biopharma Inc. broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United states [member] | $3.4M | $6.7M | $4.6M |
| Germany [member] | $3.6M | $1.4M | $2.4M |
| United kingdom [member] | $976.0K | $457.0K | |
| Other | $164.0K | $260.0K | $59.0K |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue27¢$4.9M
- Research and development16¢$3.0M
- Selling, general and admin56¢$10.1M
- Interest1¢$168.0K
- Income tax0¢$10.0K
Out of $7.5M in revenue.2 The company lost money this year.
Financial statements
No quarterly figures reported.
Every line of the income statement as filed: the last 3 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenues (note 6) | $7.5M | $9.6M | $7.1M |
| Cost of sales | -$4.9M | -$4.9M | -$4.2M |
| Gross profit | $2.6M | $4.7M | $2.9M |
| Research and development | -$3.0M | -$8.3M | -$2.0M |
| Selling, general and administrative | -$10.1M | -$10.4M | -$5.5M |
| Impairment of property and equipment (note 12) | -$240.0K | -$1.1M | |
| Write-down of inventory (note 9) | -$76.0K | ||
| Impairment of intangible assets (note 13) | -$3.2M | ||
| Total expenses | -$13.3M | -$23.0M | -$7.6M |
| Loss from operations | -$10.7M | -$18.3M | -$4.6M |
| Foreign exchange gain (loss) | -$196.0K | $48.0K | -$24.0K |
| Finance costs | -$168.0K | -$129.0K | -$136.0K |
| Interest income | $283.0K | $441.0K | $59.0K |
| Other income | $35.0K | $98.0K | $360.0K |
| Change in fair value of warrant and DSU liabilities | $379.0K | $2.6M | |
| Other income | $333.0K | $3.1M | $259.0K |
| Loss before income taxes | -$10.3M | -$15.2M | -$4.4M |
| Income tax recovery (expense) (note 22) | -$10.0K | -$84.0K | $885.0K |
| Net loss | -$10.4M | -$15.3M | -$3.5M |
| Foreign currency translation adjustments | -$961.0K | -$771.0K | $492.0K |
| Actuarial gain (loss) on defined benefit plans (note 16) | $2.0M | -$1.2M | |
| Comprehensive loss | -$9.4M | -$17.2M | -$3.0M |
| Loss per share - Basic | -$3.27 | -$5.93 | -$1.89 |
| Loss per share - Diluted | -$3.27 | -$5.93 | -$1.89 |
No quarter-by-quarter statement was filed.
No quarterly figures reported.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents (note 7) | $7.3M | $16.4M | $6.7M | $10.2M |
| Trade and other receivables (note 8) | $1.3M | $2.4M | ||
| Inventories (note 9) | $1.3M | $2.7M | ||
| Income taxes receivable | $114.0K | |||
| Prepaid expenses and other assets (note 10) | $1.6M | $2.4M | ||
| Assets held for sale (note 11) | $37.0K | |||
| Total current assets | $11.5M | $24.0M | ||
| Restricted cash and cash equivalents (note 7) | $125.0K | $123.0K | ||
| Property and equipment (note 12) | $9.8M | $11.0M | ||
| Total non-current assets | $9.9M | $11.1M | ||
| Total assets | $21.4M | $35.1M | ||
| Payables and accrued liabilities (note 14) | $1.9M | $4.7M | ||
| Provisions | $269.0K | $385.0K | ||
| Income taxes payable | $122.0K | $105.0K | ||
| Current portion of deferred revenues (note 6) | $120.0K | |||
| Current portion of lease liabilities (note 15) | $215.0K | $271.0K | ||
| Warrant liability (note 17) | $1.1M | $1.6M | ||
| DSU liability (note 18) | $48.0K | |||
| Total current liabilities | $3.6M | $7.2M | ||
| Deferred revenues (note 6) | $1.1M | $914.0K | ||
| Lease liabilities (note 15) | $1.9M | $2.0M | ||
| Employee future benefits (note 16) | $11.0M | $11.7M | ||
| Total non-current liabilities | $14.0M | $14.7M | ||
| Total liabilities | $17.6M | $21.9M | ||
| Share capital (note 19) | $22.6M | $22.5M | ||
| Contributed surplus (note 19) | $4.2M | $4.3M | ||
| Retained earnings (accumulated deficit) | -$20.5M | -$12.1M | ||
| Accumulated other comprehensive loss | -$2.4M | -$1.5M | ||
| Total shareholders equity | $3.8M | $13.2M | $21.0M | $23.8M |
| Total liabilities and shareholders equity | $21.4M | $35.1M |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents (note 7) | $7.3M | $16.4M | $6.7M | $10.2M |
| Trade and other receivables (note 8) | $1.3M | $2.4M | ||
| Inventories (note 9) | $1.3M | $2.7M | ||
| Income taxes receivable | $114.0K | |||
| Prepaid expenses and other assets (note 10) | $1.6M | $2.4M | ||
| Assets held for sale (note 11) | $37.0K | |||
| Total current assets | $11.5M | $24.0M | ||
| Restricted cash and cash equivalents (note 7) | $125.0K | $123.0K | ||
| Property and equipment (note 12) | $9.8M | $11.0M | ||
| Total non-current assets | $9.9M | $11.1M | ||
| Total assets | $21.4M | $35.1M | ||
| Payables and accrued liabilities (note 14) | $1.9M | $4.7M | ||
| Provisions | $269.0K | $385.0K | ||
| Income taxes payable | $122.0K | $105.0K | ||
| Current portion of deferred revenues (note 6) | $120.0K | |||
| Current portion of lease liabilities (note 15) | $215.0K | $271.0K | ||
| Warrant liability (note 17) | $1.1M | $1.6M | ||
| DSU liability (note 18) | $48.0K | |||
| Total current liabilities | $3.6M | $7.2M | ||
| Deferred revenues (note 6) | $1.1M | $914.0K | ||
| Lease liabilities (note 15) | $1.9M | $2.0M | ||
| Employee future benefits (note 16) | $11.0M | $11.7M | ||
| Total non-current liabilities | $14.0M | $14.7M | ||
| Total liabilities | $17.6M | $21.9M | ||
| Share capital (note 19) | $22.6M | $22.5M | ||
| Contributed surplus (note 19) | $4.2M | $4.3M | ||
| Retained earnings (accumulated deficit) | -$20.5M | -$12.1M | ||
| Accumulated other comprehensive loss | -$2.4M | -$1.5M | ||
| Total shareholders equity | $3.8M | $13.2M | $21.0M | $23.8M |
| Total liabilities and shareholders equity | $21.4M | $35.1M |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$10.4M | -$15.3M | -$3.5M |
| Depreciation and amortization | $1.2M | $1.6M | $1.4M |
| Share-based compensation costs | -$12.0K | $464.0K | $192.0K |
| Impairment of intangible assets (note 13) | $3.2M | ||
| Impairment of property and equipment (note 12) | $240.0K | $1.1M | |
| Write-down of inventory | $76.0K | ||
| Employee future benefits | $436.0K | $288.0K | |
| Amortization of deferred revenues | -$113.0K | -$856.0K | |
| Change in fair value of warrant and DSU liabilities | -$391.0K | -$2.6M | |
| Other non-cash items | $159.0K | $6.0K | $95.0K |
| Income tax (recovery) expense | $10.0K | $79.0K | -$885.0K |
| Changes in operating assets and liabilities (note 21) | $292.0K | -$2.5M | $58.0K |
| Net cash used in operating activities | -$8.5M | -$14.6M | -$2.6M |
| Exercise of stock options | $13.0K | ||
| Payments on exercise of DSUs | -$42.0K | -$167.0K | |
| Payments on lease liabilities | -$365.0K | -$421.0K | -$370.0K |
| Net cash used in financing activities | -$407.0K | -$588.0K | -$357.0K |
| Cash acquired on acquisition of Aeterna Zentaris Inc. (note 5) | $26.0M | ||
| Purchase of property and equipment | -$706.0K | -$1.2M | -$722.0K |
| Proceeds on disposal of property and equipment | $244.0K | ||
| Changes in restricted cash equivalents | $4.0K | $207.0K | -$8.0K |
| Net cash provided by (used in) investing activities | -$458.0K | $25.1M | -$730.0K |
| Effect of exchange rate changes on cash and cash equivalents | $252.0K | -$212.0K | $157.0K |
| Net change in cash and cash equivalents | -$9.1M | $9.7M | -$3.5M |
No quarter-by-quarter statement was filed.
Corporate structure
COSCIENS Biopharma Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of COSCIENS Biopharma Inc.
- Peter Puccetti Filed SCHEDULE 13D/A on COSCIENS Biopharma Inc., latest Apr 17, 2026
- Goodwood Inc. Filed SCHEDULE 13D/A on COSCIENS Biopharma Inc., latest Jun 11, 2025 (4 filings since Jun 6, 2024)
- INTRACOASTAL CAPITAL, LLC Filed SC 13G/A on COSCIENS Biopharma Inc., latest Feb 11, 2022
- Lind Global Macro Fund LP Filed SC 13G/A on COSCIENS Biopharma Inc., latest Feb 11, 2022
- COSCIENS Biopharma Inc. Toronto, Canada
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What COSCIENS Biopharma Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, net | $9.8M2 Dec 31, 2025 | $11.0M2 Dec 31, 2024 | −10.6% |
Investments
Inventory
Former names
Filings
184 filings to the SEC since October 2021: 7 annual reports, 7 large holders, 170 other. The latest 20:
- Jul 6, 202615-12G EDGAR
- Jul 6, 20266-K EDGAR
- Jul 6, 2026SC 13E3/A EDGAR
- Jun 23, 2026SC 13E3/A EDGAR
- Jun 23, 20266-K EDGAR
- Jun 18, 20266-K EDGAR
- Jun 18, 2026SC 13E3/A EDGAR
- May 20, 2026SC 13E3/A EDGAR
- May 20, 20266-K EDGAR
- May 12, 2026SC 13E3/A EDGAR
- May 12, 20266-K EDGAR
- May 12, 20266-K EDGAR
- May 8, 2026SC 13E3/A EDGAR
- May 8, 20266-K EDGAR
- May 4, 2026SC 13E3/A EDGAR
- Apr 20, 2026SC 13E3 EDGAR
- Apr 20, 20266-K EDGAR
- Apr 17, 2026SCHEDULE 13D/A EDGAR
- Apr 7, 20266-K EDGAR
- Mar 25, 202620-F EDGAR
The 184 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Peter PuccettiSCHEDULE 13D/A, 1 filing Apr 17, 202612
- Goodwood Inc.SCHEDULE 13D/A, 4 filings Jun 6, 2024 to Jun 11, 202513
- INTRACOASTAL CAPITAL, LLCSC 13G/A, 1 filing Feb 11, 202214
- Lind Global Macro Fund LPSC 13G/A, 1 filing Feb 11, 202215
SEC filer profile
How COSCIENS Biopharma Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARCOSCIENS Biopharma Inc.1
- CIK0001113423
- Filer statusNon-accelerated filer not an emerging growth company; a shell company4
- Incorporated inCanada4
- Fiscal year endsDecember 311
- Industry code (SIC)2844 Perfumes, Cosmetics & Other Toilet Preparations1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business addressC/O Norton Rose Fulbright Canada Llp, 222 Bay Street, Suite 3000, Po Box 53, Toronto, A6 M5K 1E71
- Phone843-900-32011
- Shares outstanding3,183,330 shares as of Dec 31, 20254
- AuditorDeloitte LLP, Montreal, Canada PCAOB ID 1208; no auditor attestation of internal control over financial reporting4
- On EDGAR sinceOct 24, 20001
- Filings917 in all: 6-K (613), EFFECT (34), CORRESP (23), SC 13G (22), SC 13G/A (22), POS AM (20), UPLOAD (20), 20-F (18)1
All 39 form types
SUPPL (17), 424B5 (12), 424B3 (10), SC 13D (10), 40-F (7), 6-K/A (7), SC 13E3/A (7), F-3/A (6), FWP (6), F-10 (5), F-10/A (5), F-3 (5), F-X (5), 20-F/A (4), 40-F/A (4), CT ORDER (4), F-1 (4), S-8 (4), S-8 POS (4), F-1/A (3), F-X/A (3), SCHEDULE 13D/A (3), D (2), 15-12G (1), 25 (1), 424B4 (1), 8-A12B (1), 8-A12B/A (1), F-3MEF (1), SC 13D/A (1), SC 13E3 (1)
- Latest filingsAnnual report (20-F) Mar 25, 2026
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15